- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01314677
Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation
Open Label Randomized Trial of Early Assessment of Therapy Response Using 18FDG-PET/CT in Patients With Marginally Resectable Stage IIIA (N2) Non-Small Cell Lung Cancer (NSCLC) Treated With Induction Concurrent Chemoradiation Followed by Resection and Adjuvant Chemotherapy
Panoramica dello studio
Stato
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To determine whether early response of the research positron emission tomography (PET)-computed tomography(CT) scan measured by change in Standard Uptake Value (SUV)max relative to baseline scan can predict induction chemoradiation therapy (CRT) failures sooner than post-treatment PET-CT scan.
II. To determine the optimal timing for 18FDG PET-CT that best predicts for induction CRT failure.
SECONDARY OBJECTIVES:
I. To correlate early 18 fludeoxyglucose (FDG) PET-CT response metrics with pathologic response, progression-free survival separately for: induction CRT failures vs. non-failures, or overall survival separately for induction CRT failures vs. non-failures.
OUTLINE: Patients are randomized to 1 of 3 groups.
Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.
GROUP A: Patients undergo a FDG PET/CT scan between RT fractions 5-6 (before course 2 of chemotherapy).
GROUP B: Patients undergo a FDG PET/CT scan between RT fractions 10-11 (before course 3 of chemotherapy).
GROUP C: Patients undergo a FDG PET/CT scan between RT fractions 15-16 (before course 4 of chemotherapy).
Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months thereafter.
Tipo di studio
Fase
- Non applicabile
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- All patients with marginally resectable IIIA (N2) NSCLC undergoing induction CRT will be eligible for this imaging trial; patients will be screened by the chest tumor board for entry
- Undergoing or plan to undergo induction chemoradiation
Exclusion Criteria:
- Poorly controlled or uncontrolled diabetes mellitus, with blood glucose > 200 mg/dl
- Have allergies or medical contra-indications to FDG or intravenous (IV) contrast
- Medical contra-indications to obtaining CT or PET scans
- Pre-authorization denial of coverage by insurance providers of clinical staging and restaging PET-CT scans
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Group A (FDG PET/CT between RT fractions 5-6)
Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy. Patients undergo a FDG PET/CT scan between RT fractions 5-6 (before course 2 of chemotherapy). Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection. |
Sottoporsi a FDG PET/CT
Altri nomi:
Undergo FDG PET/CT
|
Sperimentale: Group B (FDG PET/CT between RT fractions 10-11)
Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy. Patients undergo a FDG PET/CT scan between RT fractions 10-11 (before course 3 of chemotherapy). Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection. |
Sottoporsi a FDG PET/CT
Altri nomi:
Undergo FDG PET/CT
|
Sperimentale: Group C (FDG PET/CT between RT fractions 15-16)
Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy. Patients undergo a FDG PET/CT scan between RT fractions 15-16 (before course 4 of chemotherapy). Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection. |
Sottoporsi a FDG PET/CT
Altri nomi:
Undergo FDG PET/CT
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Induction therapy failure
Lasso di tempo: 6 weeks after completion of chemoradiation therapy (CRT)
|
Defined as any evidence by clinically unresectable disease based on tumor board consensus and review of restaging scans demonstrating locoregional progression or distant metastasis, surgically unresectable disease based on surgical exploration, or suboptimal resection disease still requiring pneumonectomy and still having R1 resection.
|
6 weeks after completion of chemoradiation therapy (CRT)
|
Early positron emission tomography (PET) response of group A
Lasso di tempo: Baseline and between standard radiotherapy (RT) fractions 5-6
|
Measured by the change in Standard Uptake Value (SUV)max from baseline at the research PET scan in 1 of 3 scheduled time point.
|
Baseline and between standard radiotherapy (RT) fractions 5-6
|
Early positron emission tomography (PET) response of group B
Lasso di tempo: Baseline and between standard radiotherapy (RT) fractions 10-11
|
Measured by the change in Standard Uptake Value (SUV)max from baseline at the research PET scan in 1 of 3 scheduled time point.
|
Baseline and between standard radiotherapy (RT) fractions 10-11
|
Early positron emission tomography (PET) response of group C
Lasso di tempo: Baseline and between standard radiotherapy (RT) fractions 15-16
|
Measured by the change in Standard Uptake Value (SUV)max from baseline at the research PET scan in 1 of 3 scheduled time point.
|
Baseline and between standard radiotherapy (RT) fractions 15-16
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Pathologic response
Lasso di tempo: 6 weeks after completion of chemoradiation therapy (CRT)
|
6 weeks after completion of chemoradiation therapy (CRT)
|
Progression-free survival
Lasso di tempo: Every 3 months for 2 years and every 6 months thereafter
|
Every 3 months for 2 years and every 6 months thereafter
|
Overall survival
Lasso di tempo: Every 3 months for 2 years and every 6 months thereafter
|
Every 3 months for 2 years and every 6 months thereafter
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Khanh Nguyen, City of Hope Medical Center
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie delle vie respiratorie
- Neoplasie
- Malattie polmonari
- Neoplasie per sede
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Neoplasie polmonari
- Carcinoma, polmone non a piccole cellule
- Meccanismi molecolari dell'azione farmacologica
- Radiofarmaci
- Fluorodesossiglucosio F18
Altri numeri di identificazione dello studio
- 10012 (DAIDS ES)
- NCI-2011-00337 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su fluorodesossiglucosio F 18
-
Chang Gung Memorial HospitalCompletato
-
Siemens Molecular ImagingFudan UniversityCompletatoCancro testa e collo | Cancro ai polmoni | Cancro al fegatoCina
-
Chang Gung Memorial HospitalCompletatoDemenza frontotemporale | Paralisi sopranucleare progressiva | Il morbo di Alzheimer | Compromissione cognitiva vascolare | Sindrome corticale basaleTaiwan
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletatoNeoplasie cervicali uterine | Neoplasie prostatiche | Neoplasie Rettali | Neoplasie endometriali | Neoplasie dell'anoStati Uniti
-
ABX advanced biochemical compounds GmbHCompletatoCancro alla prostata | Cancro alla prostata ricorrenteFrancia
-
Chang Gung Memorial HospitalCompletatoDisturbo depressivo maggioreTaiwan
-
Northwell HealthCompletatoTumori neuroendocriniStati Uniti
-
Brigham and Women's HospitalTerminatoAmiloidosi cardiacaStati Uniti
-
Avid RadiopharmaceuticalsCompletato
-
Case Comprehensive Cancer CenterRitiratoTumori maligni della prostataStati Uniti